Skip to main
JNJ

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 32%
Hold 37%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson is expected to have a strong year with upcoming catalysts and continued growth, despite potential risks in product launches and macro and litigation concerns. The company's diverse business portfolio, focus on innovation and sustainability, and plans for M&A and restructuring position them for success in the future. A recovery in MedTech and the goal of becoming the top oncology company by 2030 further solidifies JNJ as a strong investment option.

Bears say

Johnson & Johnson is the largest healthcare firm but has divested its consumer business, Kenvue, to focus on innovative medicine and medtech. While restructuring in 2023-24, the company has designated three main therapeutic areas: immunology, oncology, and neurology. However, there has been a decline in some of its core products, resulting in lowered sales estimates and an increasing focus on M&A rather than in-house growth strategies. Additionally, the planned separation of the Orthopaedics business in mid-2027 may pose a risk to JNJ's financials as it accounts for a significant portion of its current revenue.

JNJ has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 32% recommend Buy, 37% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 19 analysts, JNJ has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $259.26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $259.26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.